
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Free Report) – HC Wainwright issued their FY2026 earnings per share estimates for Legend Biotech in a note issued to investors on Wednesday, November 11th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings per share of $0.24 for the year. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is $0.13 per share. HC Wainwright also issued estimates for Legend Biotech’s Q1 2027 earnings at $0.14 EPS, Q2 2027 earnings at $0.22 EPS and FY2027 earnings at $1.18 EPS.
Legend Biotech (NASDAQ:LEGN – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.13. Legend Biotech had a negative return on equity of 0.03% and a negative net margin of 0.02%. The business had revenue of $359.50 million for the quarter, compared to analyst estimates of $361.46 million. During the same period last year, the company earned ($0.05) EPS. Legend Biotech’s revenue for the quarter was up 32.0% compared to the same quarter last year.
Check Out Our Latest Report on LEGN
Legend Biotech Stock Performance
NASDAQ:LEGN opened at $15.25 on Friday. Legend Biotech has a fifty-two week low of $15.15 and a fifty-two week high of $37.50. The firm has a market cap of $2.96 billion, a PE ratio of -1,523.48 and a beta of 0.55. The business has a 50 day moving average price of $19.17 and a 200-day moving average price of $22.09.
Insider Buying and Selling at Legend Biotech
In other news, Director Corazon (Corsee) D. Sanders sold 27,370 shares of the stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $9.46, for a total transaction of $258,920.20. Following the sale, the director owned 52,731 shares in the company, valued at $498,835.26. This represents a 34.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Carlos E. Santos sold 5,430 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $9.14, for a total transaction of $49,630.20. Following the completion of the transaction, the chief financial officer owned 14,246 shares of the company’s stock, valued at approximately $130,208.44. The trade was a 27.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.02% of the stock is owned by company insiders.
Institutional Investors Weigh In On Legend Biotech
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Parallel Advisors LLC lifted its holdings in Legend Biotech by 173.9% during the first quarter. Parallel Advisors LLC now owns 2,084 shares of the company’s stock valued at $38,000 after purchasing an additional 1,323 shares in the last quarter. Toth Financial Advisory Corp purchased a new position in shares of Legend Biotech during the 3rd quarter valued at $50,000. Public Employees Retirement System of Ohio bought a new position in Legend Biotech in the 2nd quarter worth $92,000. Nykredit A S purchased a new stake in Legend Biotech in the 2nd quarter worth $162,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Legend Biotech in the 3rd quarter worth $136,000. Hedge funds and other institutional investors own 70.89% of the company’s stock.
Latest Legend Biotech News
These are some of the LEGN news items that stood out recently:
- Positive Sentiment: HC Wainwright maintained its Buy rating and forecasts Legend Biotech will earn $0.24 per share in FY2026, followed by $1.18 per share in FY2027. A separate report cites a brokerage consensus price target of $50.85. Brokerage consensus price target report
- Neutral Sentiment: A recent article asks whether a return to profitability changes the investment case, but the available report details do not specify its conclusions. Yahoo Finance article on Legend Biotech’s return to profit
- Negative Sentiment: HC Wainwright cut its EPS estimates across several upcoming periods: FY2027 to $1.18 from $1.70, Q1 2027 to $0.14 from $0.26, and Q2 2027 to $0.22 from $0.36. It also reduced its Q3 and Q4 2027 forecasts. The broad revisions signal a less favorable earnings outlook and could pressure the shares, although the firm kept its Buy rating. Legend Biotech stock and analyst information
Legend Biotech Company Profile
Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.
Further Reading
- Five stocks we like better than Legend Biotech
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
